Raul Tirinescu, Oncology Specialist at M Hospital Bucharest shared a post by OncoDdaily IO on LinkedIn, adding:
“Very encouraging progress for Pembrolizumab delivery.
Same mechanism, same efficacy expectations, but a real impact on patient experience and workflow. Reducing administration from hours to minutes can significantly ease treatment burden and increase capacity in oncology units.
Important for Romania as well, reimbursement expected this year, which could facilitate rapid adoption in daily practice.
Curious how quickly subcutaneous immunotherapy will become routine.”
Quoting OncoDdaily IO‘s post:
“1-Minute Pembrolizumab: A Practical Shift in Immuno-Oncology.
The National Health Service is rolling out a subcutaneous formulation of Pembrolizumab-reducing administration time from ~2 hours (IV) to 1-2 minutes.
Key points
- Same PD-1 blockade, same efficacy intent.
- Up to 90% reduction in treatment time.
- Applicable across 14 cancer types.
- ~14,000 patients/year eligible.
Why it matters
- Less treatment burden for patients.
- More capacity for oncology units.
- No change in therapeutic mechanism.
Takeaway: Not a new drug-but a smarter way to deliver it.
A clear example of how care delivery innovation can impact real-world oncology.
Could subcutaneous immunotherapy become the default for checkpoint inhibitors?”
Other articles about immunotherapy on OncoDaily.